Paediatric Vaccinations
The ideal measure of efficacy, infection rates, is usually not studied as a primary endpoint because this requires large sample sizes. Surrogate measures such as immunogenicity are commonly used instead. Immunogenicity refers to the immune response induced by vaccination. Increased disease activity induced by vaccination and unintentional infections induced by live-attenuated pathogens in vaccines (especially in patients on high-dose immunosuppressive drugs). Another issue of vaccine safety is whether vaccines or their constituents can actually cause autoimmune disease (AID), which will be addressed briefly.
- Two doses of measles mumps rubella at 9 and 15 months of age, and no standalone measles vaccine at 9 months.
- Single dose administration of live attenuated H2 strain hepatitis A vaccine, or two doses of inactivated (killed) hepatitis A vaccine.
Related Conference of Paediatric Vaccinations
March 09-10, 2026
21th International Conference on Allergic Diseases and Clinical Immunology
Singapore City, Singapore
April 16-17, 2026
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
London, UK
Paediatric Vaccinations Conference Speakers
Recommended Sessions
- Immunopathogenesis
- Allergy, Asthma, and Immunology
- Animal & Plant-Derived Vaccines
- Child immunization and Vaccination Viral Immunology
- Clinical and Diagnostic Immunology
- Current research, and future challenges in vaccines
- DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines
- Geriatric Immunizations
- Human Vaccines-Infectious & non-Infectious
- Immunoinformatics
- Immunological Disorders
- Immunotoxicology
- Neuroendocrine Immunology
- Onco Immunology
- Paediatric Vaccinations
- Pathology and Immunology
- Psychoneuroimmunology
- Stem cell Immunology
- Vaccine & Immunization
- Vaccines against Drugs
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)